Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma

被引：27

作者：

Grohe, Christian ^{[1
]}

Gleiber, Wolfgang ^{[2
]}

Haas, Siegfried ^{[3
]}

Losem, Christoph ^{[4
]}

Mueller-Huesmann, Harald ^{[5
]}

Schulze, Mathias ^{[6
]}

Franke, Christian ^{[7
]}

Basara, Nadezda ^{[8
]}

Atz, Judith ^{[9
]}

Kaiser, Rolf ^{[10
,11
]}

机构：

[1] ELK, Dept Resp Dis, D-13125 Berlin, Germany

[2] Univ Hosp Frankfurt, Pneumol Allergol, D-60590 Frankfurt, Germany

[3] Friedrich Ebert Hosp Neumuenster, Clin Hematol Oncol & Nephrol, D-24534 Neumunster, Germany

[4] MVZ Onkol & Hamatol Rhein Kreis Neuss, D-41462 Neuss, Germany

[5] Bruederkrankenhaus St Josef, Klin Hamatol & Onkol, D-33098 Paderborn, Germany

[6] Praxis Dr Schulze, D-02763 Zittau, Germany

[7] Facharztzentrum Sonneberg, D-96515 Sonneberg, Germany

[8] Malteser Hosp, Dept Internal Med, D-24939 Flensburg, Germany

[9] Boehringer Ingelheim Pharma GmbH & Co KG, Med Affairs Oncol, D-55216 Ingelheim, Germany

[10] Boehringer Ingelheim Pharma GmbH & Co KG, D-55216 Ingelheim, Germany

[11] Johannes Gutenberg Univ Mainz, Inst Pharmacol, D-55122 Mainz, Germany

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 23期

关键词：

angio-immunogenic switch; docetaxel; nintedanib; non-small-cell lung cancer; tumor microenvironment; VARGADO; RESPONSE RATES; CANCER; CHEMOTHERAPY;

D O I：

10.2217/fon-2019-0262

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To assess outcomes in patients with advanced adenocarcinoma non-small-cell lung cancer who received nintedanib plus docetaxel after progression on prior chemotherapy followed by immune checkpoint inhibitor (ICI) therapy. Patients & methods: VARGADO is a prospective, noninterventional study. We describe initial data from a cohort of 22 patients who received nintedanib plus docetaxel after chemotherapy and ICI therapy. Results: Median progression-free survival with nintedanib plus docetaxel was 5.5 months (95% CI: 1.9-8.7 months). The objective response rate was 7/12 (58%) and the disease control rate was 10/12 (83%). Data for overall survival rate 12 months after the start of treatment (primary end point) are not yet mature and are not reported. Of 22 patients, 73% experienced drug-related adverse events; adverse events led to treatment discontinuation in 32% of patients. Conclusion: These data highlight the potential clinical benefit of nintedanib plus docetaxel in patients who failed prior ICI therapy.

引用

页码：2699 / 2706

页数：8

共 18 条

[1]

Boehringer Ingelheim, 2019, DAT FIL

[2]

Corral J, 2019, CLIN TRANSL ONCOL, DOI [10.1007/s12094-12019-02053-12097, DOI 10.1007/S12094-12019-02053-12097]

[3]

Croci DO, 2018, HANDB EXP PHARMACOL, V249, P31, DOI 10.1007/164_2017_29

[4] Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges [J].